DCTN3

Across TCGA pan-cancer cohorts, DCTN3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DCTN3 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DCTN3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DCTN3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where DCTN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.339	0.799	.001	24	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	21	view →
PDAC	OS	Tertile	All	0.544	0.316	.001	16	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
HNSC	DFS	Median	III,IV	0.885	0.692	.015	4	view →
LSCC	OS	Median	All	0.740	0.874	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DCTN3–LUAD (OS)

Open the LUAD breakdown →